Considerations in FIrst-Line Therapies for Treatment-Naive Chronic Hepatitis B

Main Article Content

John Ryan, Christian Stone Syed Abdul-Basit, Karina Herrera



The treatment of chronic Hepatitis B Virus (CHBV) infection has evolved considerably during the last decade.  As the number of potential therapies has grown, so has the relative complexity of managing the disease.  There are now five oral nucleoside/nucleotide analogues and two injectable versions of interferon that are approved for the treatment of CHBV.  Of these, the American Association for the Study of Liver Diseases (AASLD) now recommends only entecavir, tenofovir, and pegylated interferon as first-line options for treatment-naïve individuals.1,2  Each has some potential advantages and disadvantages that should be weighed prior to making a choice for what is generally long-term therapy.

Article Details

How to Cite
SYED ABDUL-BASIT, KARINA HERRERA, John Ryan, Christian Stone. Considerations in FIrst-Line Therapies for Treatment-Naive Chronic Hepatitis B. Medical Research Archives, [S.l.], n. 3, may 2015. ISSN 2375-1924. Available at: <>. Date accessed: 21 apr. 2018.
Review Articles

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.